Linked Life Data

21306205

Source:http://linkedlifedata.com/resource/pubmed/id/21306205

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-2-10
pubmed:abstractText
Sugammadex is the first in a new class of medications termed selective relaxant binding agents. This medication acts to encapsulate free circulating steroidal nondepolarizing neuromuscular blocking agents. The encapsulation of neuromuscular agents effectively decreases the amount of neuromuscular blocker interacting at the neuromuscular receptor. This binding has a very high association rate, rendering the incidence of residual block extremely low, while avoiding the side effects associated with traditional reversal agents. Currently approved for clinical use in over 50 countries, sugammadex was not approved by the US FDA in 2008 due to concerns over potential hypersensitivity reactions. It is hoped that further study and clinical experience will help to better define the risk associated with sugammadex and eventually lead to the approval of this novel medication in the USA.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1744-8360
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
185-98
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Sugammadex: a novel approach to reversal of neuromuscular blockade.
pubmed:affiliation
Mayo Clinic, Department of Anesthesiology, 4500 San Pablo Rd, Jacksonville, FL 32224, USA. aniskevich.stephen2@mayo.edu
pubmed:publicationType
Journal Article, Review